2023 年深度行业分析研究报告 内容目录内容目录 1.需求端：呼吸道传染疾病高发，临床呼吁易于普及的联检产品.5 1.1.国内回顾：“管控政策优化后第一年”，各种病原体呈接力式爆发.6 1.2.海外. 

0人已浏览 2024-01-31 35页 5星级

2 0 1 8.7-2 0 2 3.6?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATION?!?!?!?!?!?2023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|2023?1.1?1.2?2.1?2.1.1?2.1.2?2.2?2.2.1?2.2.2?2.2.3?2.2.4?2.3?2.4?3.1?3.1.1?3.1.2?3.1.3?3.1.4?3.2?3.2.1?3.2.2?3.2.3?3.2.4?06081024?2023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20233.3?3.3.1?3.3.2?3.3.3?3.3.4?3.4?3.4.1?3.4.2?3.5?3.5.1?4.1?4.2?4.3?4.4?59?5.1?5.1.1?5.1.2?5.1.3?5.2?5.2.1?5.2.2?68?6.1?6.2?6.3?75?81?872023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|2023?061.?2.?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?074.?5.?3.?RETINAL AI BASED BLUE PAPER ON THE HEALTH OFFOUR MILLIONMEDICAL EXAMINATION POPULATIONChapter.01?2023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|2023?09?0.1%9.4.3%8.6%8.6%6.0%0.1%9.0.5.2%9.2%6.0%?!#$%&!#$%&()*#$ ,-.(#$%&)*#$ ,-.)#$%&!#$%&/)*#$ ,-,?48.0%1,952,041?52.0%2,116,035?RETINAL AI BASED BLUE PAPER ON THE HEALTH OFFOUR MILLIONMEDICAL EXAMINATION POPULATIONChapter.02?2023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|2023?11?* ,-(./01?38.6S.2e.9.0.8.25.4P.2a.4.5.8.2%?78.4%?75.9%!#$%&(#%&)!#*%& (#*%& *#*%& *#$%&?2023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|202312?521,56717.3A0,33378.7%2,1460.41%?384,64012.88,12972.3%1,3120.34%?370,45712.3&9,61372.8%1,3420.36%?304,17410.16,51674.5%1,0870.36%?283,7869.4!0,25774.160.29%?241,5898.08,57482.2%1,4490.60%?188,2786.31,92975.4p80.38%?180,9916.07,88670.7D50.25%?175,1315.83,78670.700.34%?137,1064.64,24576.0Y20.43%?67,6662.3V,87984.160.60%?39,6551.32,34281.630.44%?37,4811.2(,84076.960.42%?30,1581.0#,80778.910.40%?20,2120.7,74377.90.45%?15,5040.5,14178.30.39%?4,6370.2%3,45174.4)0.63%?3,0850.1%2,61584.8!0.68%?3380.0&377.8.30123RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?13?!?!?42.9%?2?!?!?!?!?!?!?!?!?!?!?!?!?!?!?!?!?!?!?!?!?!?!?!?!?!?!?36.0G.83.9%8.3%4.9 23?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|202314?!?!?!?!?9,3910.23%!?!?!?!?8,1230.20%!?!?!?9500.02%!?!?2650.01%!?!?!?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?15?62901,4202,5086,0727,5490.0%0.0%0.1%0.3%0.8%1.5%-1.00%-0.50%0.00%0.50%1.00%1.50%!#$#%&#&#(&#)&#&#*&# &#,&#-&#?!#$%&(!#$%&!#$%)* (%)2023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|202316?8.2.0$.66.7Q.8X.0%?1,380,888?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?17?1.8%2.6.6t.8.4.3%?1,944,763?2023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|202318?37.85.75.76.5%?43.8H.7H.2P.3%?35.34.33.33.2%?8.7%8.0%8.4%8.0%?3.0%4.5%5.2%6.5%?76.1w.4w.4x.7%?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?19?2023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|202320?6.7%6.0%6.8%8.3%9.8.2%?335,640?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?21?53.910,215?46.1&4,835?575,050?78.0w.3%?48.6G.1%?012-3401.- 42023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|202322?763?187?4,177?33?58?2?119,041?1,242?4,464?21?24.5%?0.8%?3.5%?1.0%?0.5%?524?69?13.2%?9,640?382?4.0%?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?23?18?2?749?56?443?35?2?25?26?76?6?33?130?1?2?1?3?RETINAL AI BASED BLUE PAPER ON THE HEALTH OFFOUR MILLIONMEDICAL EXAMINATION POPULATIONChapter.03?2023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|2023?25?0.1%0.1%0.1%1.2%4.3%5.1%0.0%0.0%0.0%0.6%2.5%4.4%?52.1%1,906,643?47.9%1,749,458?3,656,101?40,524?1.1%?61,375?1.7 23?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|202326?0.1%0.2%1.1%7.4.6A.1%0.0%0.0%0.0%0.9%4.8%8.8%?52.1%1,906,643?47.9%1,749,458?3,656,101?77,565?2.1%?396,201?10.8%?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?0.2%1.0%4.4(.9%?27?025507510056789:567!89:567!;9:567;9:?2023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|202328?0.0%0.1%0.3%8.4%?02550751006789:67!89:67!;9:300mg?150-300mg?89:=?!89:=?!;9:=?;9:?4.6.8$.63.0%?2023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|202342?14.9.9.5!.8.8.4.9%?50.9%?49.1.4%?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?43?15.9.3%?1.1?15.8.0%?1.2?2023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|202344?0.0.45.3 .4.2.6%?54.1(7,808?45.9$4,360?532,168?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?0301 97 86,795 462 184,309 626 101,940 817 73,958 902 47,409 45?494,712?2,904?0.6%?0.0%0.1%0.3%0.6%1.1%1.9%?2,904?494,712?0.6 23?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|202346?0.1%0.2%0.9%2.4%?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?4.0%6.4.3.60.5.9%2.9%2.5%4.7.2Q.0w.8%?47?52.1%1,906,643?47.9%1,749,458?3,656,101?865,119?23.7%?653,140?17.9%?2023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|202348?80-120 60-80?121-139 81-89?140901.1%5.9.7e.6%?0255075100;689:;6!89:;6!;9:;6;9:?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?49?22.1B.8T.1Q.9%?0255075100;689:;6!89:;6!;9:;6;9:?2023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|202350?22.9.0%.3%.6%.1%.3.2%?50.9%?49.1.4%?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?51?23.8&.1%?1.1?24.2.4%?1.1?25.2(.0%?1.1?2023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|202352?0.0.45.3 .4.2.6%?54.1(7,808?45.9$4,360?532,168?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?2 283 688 82,576 2,086 172,052 2,028 88,195 2,091 55,659 1,894 27,774 53?426,539?8,789?2.1%?0.7%0.8%1.2%2.3%3.8%6.8%?8,789?426,539?2.1 23?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|202354?0.4%1.5%3.6%6.5%?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?0.3%0.1%0.2%0.2%0.2%0.6%2.4%2.3%3.9%6.5%1.6%0.4%?55?52.0%1,719,457?48.0%1,584,191?3,303,648?54,565?1.7%?237,032?7.2%?* ,-(./011.2%1.3%1.9%3.1%0.9%0.5 23?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|202356?0.5%4.4.8.8%?0255075100A689:A6!89:A6!;9:A6;9:?115g/L?130g/L?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?57?2023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|2023580.1%0.0%0.0%0.1%5.1).4%0.0%0.0%0.0%0.0%0.3%2.1%?52.5%1,000,039?47.53,133?1,903,172?5,959?0.3%?86,075?4.5%RETINAL AI BASED BLUE PAPER ON THE HEALTH OFFOUR MILLIONMEDICAL EXAMINATION POPULATIONChapter.04?2023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|202360?Deep learning algorithm using fundus photographs for 10-year risk assessment of ischemic cardiovascular diseases in China?Science Bulletin/20.577?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?61?2023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|202362?Development and validation of a deep learning algorithm based on fundus photographs for estimating the CAIDE dementia risk score?Age and Ageing/12.782?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?63?2023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|202364?Artificial Intelligence for Screening of Multiple Retinal and Optic Nerve Diseases?JAMA Network Open/13.353?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?65?2023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|202366?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?Retinal photograph-based deep learning system for detection ofhyperthyroidism:a multicenter,diagnostic study?Journal of Big Data/10.835?67?RETINAL AI BASED BLUE PAPER ON THE HEALTH OFFOUR MILLIONMEDICAL EXAMINATION POPULATIONChapter.05?2023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|2023?-3.00?-1.00D-6.00?-3.00D-6.00D?1.62.64.6?2.33.314.4?3.28.712.6?13.672.784.5?692023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|2023?70RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?712023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|2023?72RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?732023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|2023?74RETINAL AI BASED BLUE PAPER ON THE HEALTH OFFOUR MILLIONMEDICAL EXAMINATION POPULATIONChapter.06?2023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|2023?76RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?772023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|2023?78RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?792023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|2023?80RETINAL AI BASED BLUE PAPER ON THE HEALTH OFFOUR MILLIONMEDICAL EXAMINATION POPULATIONChapter.07?2023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|2023?82RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?!?832023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|2023?84RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?852023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|2023?86RETINAL AI BASED BLUE PAPER ON THE HEALTH OFFOUR MILLIONMEDICAL EXAMINATION POPULATIONChapter.08?2023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|2023?88RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|20232023?892023?RETINAL AI BASED BLUE PAPER ON THE HEALTH OF FOUR MILLIONMEDICAL EXAMINATION POPULATIO|2023?90!#$%&()* ,-./0123456789:#;=?/A77BB9:#;=?/A77B.C#DDDAEFGHIAJKL?

0人已浏览 2024-01-25 91页 5星级

请务必阅读正文后的声明及说明请务必阅读正文后的声明及说明 Table_Info1 医药生物医药生物 Table_Date 发布时间：发布时间：2023-06-29 Table_Invest 优于大势.

81人已浏览 2023-06-30 30页 5星级

点击查看更多艾社康：2021中国卫生健康服务体系创新案例集（64页）.pdf精彩内容。

127人已浏览 2022-11-21 64页 5星级

行业集中度得到显著提升，区域供需错配和砂石供应紧张情形频现，骨料价格近年呈稳步上升态势。

96人已浏览 2022-01-13 29页 5星级

前 言体外诊断是临床诊断信息的重要来源，其贯穿于初步诊断、治疗方案选择、治疗检测、预后及体检等疾病治疗全过程，为医生治疗方案及用药提供重要参考指标，是现代疾病和健康管理不可或缺的一环。根据罗氏诊断数据.

564人已浏览 2021-12-02 57页 5星级

燃石医学成立于 2014 年，专注于为肿瘤精准医疗提供最具临床价值的二代基因测序(NGS)产品及服务。目前业务覆盖三大板块：肿瘤患病人群检测、癌症早筛早检及肿瘤基因组大数据生态圈。无论是创新技术、贴近.

156人已浏览 2021-09-07 17页 5星级

截止2020年12月31日，全球已经近20家人工智能+健康医疗大数据公司完成新一轮融资，其中不乏森亿智能和零氪科技一类的成熟公司，完成了D轮融资；同时一些初创公司也在崛起。 该类公司的产品与服务面向企. 

437人已浏览 2021-07-29 20页 5星级

整体产能加速扩张，保证长期成长。2020 年公司研发实验室、工厂和办公场地面积约 83.8 万平方米，同比增长 34.7%。其中中国区实验室方面，2020 年 7 月，公司位于成都的研发中心正式投入运.

149人已浏览 2021-07-29 47页 5星级

烤片：将带有蜡的组织切片黏在载玻片上，以免染色过程中切片脱落 脱蜡和水化：通过二甲苯进行脱蜡，然后使用下行梯度乙醇将组织中二甲苯替代出来 抗原修复：部分抗原肽链经过此前步骤处理后发生扭曲，无法在免疫.

118人已浏览 2021-07-29 76页 5星级

全结肠镜检查是结直肠癌筛查中非常重要的确诊手段，也可作早期治疗，在直视下对结直肠癌、腺瘤或息肉进行摘除治疗。然而在结肠镜检查和治疗过程中，穿孔和出血是常见的并发症，处理不当会危及生命。经验不足和操作粗. 

374人已浏览 2021-07-28 144页 5星级

 友邦保险：科技赋能健康管理，帮助客户养成良好健康习惯，为客户提供解决方案。针对患病前管理：在国际市场，友邦保险与南非 Discovery 公司合作，推行“AIAVitality 健康程式”计划，通过健.

389人已浏览 2021-07-23 62页 5星级

产业基金在公司的扩张过程中功不可没。从公司 2018 年披露的数据来看，公司与南通基金、嘉兴信文、上海健亿等基金合作，共投资 108 家体检中心，2019 年 2 月再次与南通基金投资 6 家体检中心.

350人已浏览 2021-07-22 28页 5星级

从历史收入增速上来看，2015 年-2018 年，其收入规模快速增长，主要受体检中心数量扩张，从而拉动体检人次上涨所致。其体检中心数量，从 2014 年的 94 家上涨至 2018 年的 633 家，.

192人已浏览 2021-07-22 43页 5星级

如果说美年健康进军低级别城市是广度扩张，那么塑造美兆健康、慈铭奥亚的高端品牌就是深度扩张。以美兆健康为例，其定位就是高端的全方位健康管理，其服务分为检查、评估、促进三个阶段，通过检测、监测、分析、评估.

453人已浏览 2021-07-22 46页 5星级

政策不断推进智慧医院实现以信息化和大数据为导向的精细化管理。2020 年 5 月，国家卫健委发布关于进一步完善预约诊疗制度加强智慧医院建设的通知，推动进一步建立完善预约诊疗制度，从智慧服务、电子病历、.

54人已浏览 2021-07-21 19页 5星级

 医学研究所(IOM)对初级保健未来的研究于1994年初启动，旨在影响当时的医疗改革漩涡。

33人已浏览 2021-07-16 449页 5星级

 焦点福瑞达为全球第二大透明质酸原料生产商，产能持续扩张。公司旗下焦点福瑞达生物股份有限公司目前拥有食品级和化妆品级透明质酸 420 吨/年的产能，其中 2019 年前原有产能 120 吨/年，2019.

51人已浏览 2021-07-15 22页 5星级

 公司已建立完整的医疗运营体系，精细化、合规化运营能力强。香港医疗行业监管严格，医疗机构及执业医生信息透明化公开化。与内地私营医疗机构相比，在香港运营私营医疗机构需要更高的精细化、合规化管理能力。同时，.

55人已浏览 2021-07-08 42页 5星级

 公司是中国独立临床特检行业的领导者，也是血液学特检服务的主要供应商。在过去17年中，已建立全面的检测组合、广泛的医院网络及先进的技术平台，提供超过3,500种检验项目，在血液学、遗传病及罕见病、传染病. 

59人已浏览 2021-07-01 18页 5星级